Treatment Advances and Evolving Standard of Care in Atopic Dermatitis - Episode 14
Long-term Safety of JAK Inhibitors in Atopic Dermatitis
Following a review of findings from the LEVEL UP study, an expert on atopic dermatitis shares what we’ve learned from long-term data on upadacitinib and JAKi.
Video content above is prompted by the following:
- Are there any learnings from long-term upadacitinib data that were not seen in short-term data?
- What about short vs long-term data with other JAKi?
- How do they impact your use of JAKi for atopic dermatitis?
